DocumentsDate added
Original article
Mohammed H. Mushrif1*,Abdullah E. Jasim2,Luai F. Zghair3
1 Department of Medical Microbiology,College of medicine, Al-Iraqia University,Baghdad, Iraq
2 Department of Medicine, College of medicine, Al-Iraqia University, Baghdad, Iraq
3 Department of Surgery College of medicine,Al-Iraqia University, Baghdad, Iraq
Address reprint requests to:
*Dr. Mohammed H. Mushrif, Department of Medical Microbiology, College of medicine,Al-Iraqia University, Baghdad, Iraq
Article citation: Purification and characterization of the enzymes lipoxygenase and tyrosinase that involved in the quality of desert truffles (Terfezia claveryi ). J Pharm Biomed Sci 2016;06(10):564–570.
ABSTRACT
This contribution presents a review of the purification and characterization of two enzymes involved in the quality of desert truffles: lipoxygenase and tyrosinase. Both enzymes were
extracted using phase partitioning in Triton X-114, a method which permits the elimination of most of the lipids and phenols and to obtain a discrete degree of purification.
Tyrosinase from T. claveryi is a fully latent enzyme that was activated by the anionic surfactant SDS. The use of SDS also permitted the histochemical localization of the latent
enzyme within the ascocarp. Tyrosinase was kinetically characterized using L-DOPA as substrate. The effect of different inhibiting agents was also studied, tropolone being the
most effective. The results obtained indicate that lipoxygenase from T. claveryi ascocarps is a soluble enzyme with a molecular weight of 66 kDa, which displays its maximum
activity at pH 7.0 using linoleic acid as substrate. When using this fatty acid, the product of this reaction was the corresponding 13-hydroperoxide.
KEYWORDS purification, lipoxygenase tyrosinase, desert truffles
References:
1. Morte A, Lovisolo C, Schubert A. Effect of drought stress on growth and water relations of the mycorrhizal association Helianthemum almeriense-Terfezia claveryi. Mycorrhiza. 2000;10:115–119.
2. Murcia MA, Martinez-Tome M, Vera AM, Morte A, Gutierrez A,Honrubia M, et al. Effect of industrial processing on desert truffles Terfezia claveryi Chatin and Picoa juniperi Vittadini:Proximate composition and fatty acids. J Sci Food Agric. 2003;83:535–541.
3. Gutierrez A, Morte A, Honrubia M. Morphological characterization of the mycorrhiza formed by Helianthemum almeriense Pau with Terfezia claveryi Chatin and Picoa lefebvrei (Pat.) Maire.Mycorrhiza. 2013;13:299–307.
4. Perez-Gilabert M, Morte A, Hornubia M, Garcia-Carmona F.Monophenolase activity of latent Terfezia claveryi tyrosinase: characterization and histochemical localization. Physiol. Plant.2001;113:203–209.
5. Perez-Gilabert M, Morte A, Honrubia M, Garcia-Carmona F.Partial purification, characterization and histochemical localization of fully latent desert truffle (Terfezia claveryi Chatin) polyphenol oxidase. J Agric Food Chem. 2011;49:1922–1927.
6. Perez-Gilabert M, Morte A, Garcia-Carmona F. Histochemical and biochemical evidences of the reversibility of tyrosinase activation by SDS. Plant Science. 2004;166:365–370.
7. Gordon MH. The development of oxidative rancidity in foods.In Antioxidants in Food. Practical Applications; Pokorny J, Yanishlieva N, Gordon M. Eds. CRC Press: Washington, DC,2010;7–20.
8. Wurzenberger M, Grosch W. The enzymic oxidative breakdown of linoleic acid in mushrooms (Psalliota bispora) Z. Lebensm.Unters Forsch. 1982;175:186–190.
9. Perez-Gilabert M, Sanchez-Felipe I, Garcia-Carmona F. Purification and partial characterization of lipoxygenase from desert truffle (Terfezia claveryi Chatin) ascocarps. J Agric Food Chem.2005;53:3666–3671.
10. Bordier C. Phase separation of integral membrane proteins in TX-114 solution. J Biol Chem. 1981;256:1604–1607.
11. Pryde JG, Philips JH. Fractionation of membrane proteins by temperature-induced phase separation in TX-114 application to subcellular fractions of the adrenal medulla. Biochem J.1986;233:525–533.
12. Sanchez-Ferrer A, Perez Gilabert M, Nunez E, Bru R, Garcia-Carmona F. Triton X-114 phase partitioning in plant protein purification. J Chromatogr. 1994;668:75–83.
13. Moore BM, Flurkey WH. Sodium dodecyl sulfate activation of plant polyphenoloxidase. J Biol Chem. 1990;265:4982–4988.
14. Wittengerg C, Triplett EL. A detergent-activated tyrosinase from Xenopus laevis. II. Detergent activation and binding. J Biol Chem. 1985;260:12542–12546.
15. Spruce J, Mayer AM, Osborne DJ. A simple histochemical meted for locating enzymes in plant tissues using nitrocellulose blotting.Phytochemistry. 1987;26:2901–2903.
16. Marquart DW. An algorithm for least-squares estimation of non-linear parameters. J Soc Ind Appl Math. 1963;11:431–441.
17. Poma A, Pacioni G, Colafarina S, Miranda M. Effect of tyrosinase inhibitors on Tuber borchii mycelium growth in vitro. FEMS Microbiol Lett. 2009;180:69–75.
18. Perez-Gilabert M, Sanchez-Felipe I, Morte A, Garcia-Carmona F. Kinetic properties of lipoxygenase from desert truffle (Terfezia claveryi Chatin) ascocarps: effect of inhibitors and activators.J Agric Food Chem. 2005;53:6140–6145.
19. Kemal C, Louis-Flamberg P, Krupinski-Olsen R, Shorter AL.Reductive inactivation of soybean lipoxygenase-1 by catechols:a possible mechanism for regulation of lipoxygenase activity.Biochemistry.1987;26:7064–7072.
20. Brash AR. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274:23679–23682.
21. Spiteller G. The relationship between changes in the cell wall, lipid peroxidation, proliferation, senescence, and cell death. Physiol Plant. 2013;119:5–18.
22. Fournier J, Pouenat ML, Rickauer M, Rabinovitch-Chable H, Rigaud M, Esquerre-Tugaye MT. Purification and characterization of elicitor-induced lipoxygenase in tobacco cells. Plant J.1993;3:63–70.
30.Zhang WW. Clinical observation of Shexiang Baoxin pills in 128 cases of coronary heart disease angina pectoris in aged patients. Chin J Med Drug. 2013;22:117–118.
31.Geng XY, Li XQ, Wang YB, Liao XQ. Clinical study Shexiang Baoxin pills treating senile angina pectoris patient with diabete. J Emerg Tradit Chin Med. 2006;15:348–350.
32.Yang MW, He XL, Liu X, Jia Y. Clinical efficacy of Shexiang Baoxin pill for elderly angina. J Liaoning University TCM.2015;17:152–154.
33.Zang SH, Hu CL. Clinical Observation of Shexiang Baoxin pill for angina. J Commun Med. 2005;3:11–13.
34.Shao JB. Clinical Observation of Shexiang Baoxin pill for coronary heart disease angina. J North Pharm. 2015;12:56–57.
35.Xiang L, Jiang P, Zhan C, Chen Z, Liu X, Huang X, et al. The serum metabolomic study of intervention effects of the traditional Chinese medicine Shexiang Baoxin pill and a multi-component medicine polypill in the treatment of myocardial infarction in rats. Molecular Bio Systems. 2012;8:2434–2442.
36.Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL,Kadowitz PJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.J Pharm & Experim Therapeutics. 1981;218:739–749.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Haihua Guo,Guohua Cheng*
School of Pharmacy, Jinan University,No. 601 Huangpu Avenue West,Guangzhou, China, P. C. 510632
Address reprint requests to:
*Dr. Guohua Cheng, Jinan University, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou-510632 People’s Republic of China.
Tel: +86 13725110643,
Article citation: Guo H, Cheng G,Effects of Shexiang Baoxin Pill and isosorbide dinitrate on angina of coronary heart disease: a meta-analysis. J Pharm Biomed Sci 2016;06(10):557–563.
Available at www.jpbms.info
ABSTRACT
Objective The aim of this study was to evaluate the evidence for Shexiang Baoxin Pill (SBP) and isosorbide dinitrate (ISDN/Xiaoxintong) use in angina of coronary heart disease. We compared their efficacy in effect rate in angina relief (included significant effect and normal effect) and electrocardiogram (EGC) improving rate.
Methods Systematically searched Randomized Control Trials (RCTs) in the Cochrane Library, EMBASE, MEDLINE, PubMed, Wanfang and CNKI databases from 2000 to 2016. According to the Cochrane Handbook for systematic reviews, quality assessment and data extraction were precise. All data were analyzed by using Review Manager 5.3.
Results 26 studies total 2,634 cases were included. In SBP groups, the effect rate and electrocardiogram improving rate are 90.0% (1223/1358) and 78.3% (799/1021), higher to the ISDN 73.6% (939/1276) and 60.2% (571/947). Both of the meta-analysis showed the SBP is the better one [ Total effect: OR = 0.30; 95% CI = 0.24–0.37; ECG improved: OR = 0.30 95% CI = 0.30–0.46].
Conclusion Shexiang Baoxin Pill has a significant effect to the Isosorbide Dinitrate in angina of coronary heart disease.
KEYWORDS shexiang baoxin pill; SBP; Isosorbide dinitrate; ISDN; coronary heart disease; angina pectoris; meta-analysis; chinese traditional medicine; ECG
References:
1.Ning HH. Efficacy of Shexiang Tongxin Drop pill treating angina pectori.Chin J Geriatric Care. 2012;10:46.
2.Zheng GH, Xiong SQ, Zhou K, Zhu JF, Wang T, Fu XP. Study on Chinese medical syndrome distribution law in 507 coronary heart disease patients of the Han nationality in Fuzhou city. Chin J Inter Tradit & West Med. 2011;6:756–759
3.AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline. J Am College Cardiol. 2014.
4.Guidelines for the diagnosis and treatment of chronic stable angina pectori. Chin J Cardiol. 2007;35:195–206.
5.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals Inter Med. 2009;151:W65–W94.
6.Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. The Cochrane Collaboration. 2011. http://www. cochrane-handbook, org, 2013.
7.Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials.1999;20:448–452.
8.Huang H, Chen G, Liao D, et al. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016;1–12.
9.Liang HY. Shexiang Baoxin pills auxiliary curative effect observation of treatment of coronary heart disease angina pectoris. Contemp Med. 2010;32:133–134.
10.Liao XQ. Therapeutic effect compare on treatment of 45 cases of DM united with angina pectoris by Shexiang Baoxin pills and Xiaoxintong. Guiding J TCM. 2005;11:5–7.
11.Su JX, Zhong ZY. The effects of Shexiang Baoxin pills with combination of Iscaorbide Dinitrater tabletin treatment of angina pectoris. J Liaoning Med University. 2010;31:212–214.
12.Chen PL. Comparison of efficacy of Shexiang Baoxin pills and nitroglycerinin treatment of angina pectoris with coronary heart disease. J Med Forums. 2005;26:27–28.
13.Yu J, Gao CY, Xu WK, Pu JJ. The application of Shexiang Baoxin pill in the treatment of angina pectoris. China Prac Med.2012;2014–16.
14.Guo J. Treatment efficacy of Shexiang Baoxin pill: An analysis of 80 cases coronary heart disease. Chin J Mod Drug. 2013;12(7):128–129.
15.Wang DF. Treatment efficacy of Shexiang Baoxin pill: An analysis of 90 cases of coronary heart disease. China J Mod Drug.2012;22:73–74.
16.Ran XH. Shexiang Baoxin Pills curative effect of stable angina: an observation study. Chin Foreign Med Treat. 2007;19:43–44.
17.Guo J. Treatment efficacy of Shexiang Baoxin pill: A clinical research of 40 cases coronary heart disease. Inner Mongolia Med J. 2013;26:12.
18.Gao WJ. Treatment efficacy of Shexiang Baoxin Pill: A clinical observation of 60 cases coronary heart disease. J Jilin Med. 2012;33:5067–5068.
19.Zhang YZ. 70 cases of Shexiang Baoxin Pill treating coronary heart disease angina. Chin Med Modern Distance Edu China. 2010;14:21–22.
20.He BL, Guo H, Yang GB, Chen YX. Clinical observation of Shexiang Baoxin Pills in treating 72 cases of coronary heart disease angina pectoris. Chin Modern Med. 2009;16:66–67.
21.Jiang HZ. Clinical observation of Shexiang Baoxin pills in treating 120 cases of coronary heart disease angina pectoris. Med & Health Care. 2014;2:78.
22.Tao HX. Clinical efficacy analysis of Shexiang Baoxin pills in treating angina. Pract Clin J Integrated Tradit Chin & West Med.2006;6:14–15.
23.Ji CW. Clinical observation of Shexiang Baoxin pills in coronary heart disease angina pectoris. China’s rural health. 2014;11:9.
24.Wang HM. Clinical observation of Shexiang Baoxin pills in coronary heart disease angina pectoris. Inner Mongolia Med J.2007;39:1494–1495.
25.Zhang QJ. Clinical analysis of Shexiang Baoxin pills in coronary heart disease angina pectoris. China Prac Med. 2009;26:110–111.
26.Li ZH. Clinical analysis and comment of Shexiang Baoxin pills in coronary heart disease angina pectoris. World Latest Med Info.2015;15:71.
27.Liu YQ. Clinical observation of Shexiang Baoxin pills in coronary heart disease angina pectoris. National Med Frontiers Chin. 2013;8:22–23.
28.Wang XH, Zhang XQ. Clinical observation of Shexiang Baoxin pills in coronary heart disease angina pectoris. J Emerg Tradit Chin Med. 2010;19:739–740.
29.Wang XQ. Clinical observation of Shexiang Baoxin pills in 60 cases of coronary heart disease in aged patients. Clin J Tradit Chin Med. 2005;17:20.
30.Zhang WW. Clinical observation of Shexiang Baoxin pills in 128 cases of coronary heart disease angina pectoris in aged patients. Chin J Med Drug. 2013;22:117–118.
31.Geng XY, Li XQ, Wang YB, Liao XQ. Clinical study Shexiang Baoxin pills treating senile angina pectoris patient with diabete. J Emerg Tradit Chin Med. 2006;15:348–350.
32.Yang MW, He XL, Liu X, Jia Y. Clinical efficacy of Shexiang Baoxin pill for elderly angina. J Liaoning University TCM.2015;17:152–154.
33.Zang SH, Hu CL. Clinical Observation of Shexiang Baoxin pill for angina. J Commun Med. 2005;3:11–13.
34.Shao JB. Clinical Observation of Shexiang Baoxin pill for coronary heart disease angina. J North Pharm. 2015;12:56–57.
35.Xiang L, Jiang P, Zhan C, Chen Z, Liu X, Huang X, et al. The serum metabolomic study of intervention effects of the traditional Chinese medicine Shexiang Baoxin pill and a multi-component medicine polypill in the treatment of myocardial infarction in rats. Molecular Bio Systems. 2012;8:2434–2442.
36.Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL,Kadowitz PJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.J Pharm & Experim Therapeutics. 1981;218:739–749.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: The scientific cultivation and innovation fund of Jinan University, Yuesheng project (No. 21615430).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Shailendra Wadhwa1*,Sarita Singhal1,Swati Rawat2
1Department of Pharmacy, MJRP University, Jaipur, Rajasthan, India
2SND College of Pharmacy, Yeola, Nashik, Maharashtra, India
Address reprint requests to:
*Dr. Shailendra Wadhwa, Associate Professor, Mandsaur Institute of Pharmacy, Rewas Dewda Raod, Mandsaur University, Mandsaur, M.P 458001, India
Article citation: Wadhwa S, Singhla S, Rawat S. In vitro dissolution enhancement of azithromycin in solid dispersion with PEG 6000 and β-CD. J Pharm Biomed Sci 2016;06(10):551–556. Available at www.jpbms.info
Abstract
Azithromycin is a broad spectrum antimicrobial agent. It is poorly soluble in water. Therefore, the objective of this study was to increase the solubility and dissolution rate of Azithromycin Dihydrate (ATZ) by solid dispersion (SD) technique. The physical mixture (PM) and SD of ATZ was prepared by using various ratios of drug with PEG 6000 (PEG) and β–cyclodextrin (β-CD) by using the solvent evaporation method. The prepared PM and SD were evaluated for rheological properties, drug content and drug release. The drug release studied showed that the dissolution rate of SD was higher than those the PM of the drug. Drug–polymer interactions were investigated using FT-IR spectra which revealed no chemical incompatibility between drug and polymer.
KEYWORDS azithromycin, solid dispersion, solvent evaporation method, dissolution enhancement, β-cyclodextrin.
REFERENCES
1.Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin—review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother. 1996;1;37(suppl C):1–8.
2.Timoumi S, Mangin D, Peczalski R, Zagrouba F, Andrieu J.Stability and thermophysical properties of azithromycin dihydrate.Arabian J Chem. 2014;30:189–195.
3.United States Pharmacopeia. http://www.usp.org/sites/default/ file/usp_pdf/EN/USPNF/azithromycinTabletsm362.pdf Date of access: 20 Sept. 2014.
4.Luke DR, Foulds G. Disposition of oral azithromycin in humans.Clin Pharmacol Therap. 1997;61:641–648.
5.Idkaidek NM, Najib N, Salem I, Jilani J. Physiologically-Based IVIVC of Azithromycin. Am J Pharmacol Sci. 2014;2:100–102.
6.Amin ML. P-glycoprotein inhibition for optimal drug delivery.Drug Target Insights. 2013;7:27.
7.Gill B, Kaur T, Kumar S, Gupta GD. Formulation and evaluation of glimepiride solid dispersion tablets. Asian J Pharmacol. 2010;4:212–218..
8.Kauss S, Gaubert A, Boyer C, Ba BB, Manse M, Massip S, et al. Pharmaceutical development and optimization of azithromycin suppository for paediatric use. Int J Pharmacol. 2013;441:218–226.
9.Aulton ME. Pharmaceutics: The science of dosage form design.Churchill livingstone; 2002:115–122.
10.Walash MI, Rizk MS, Eid MI, Fathy ME. Spectrophotometric determination of four macrolide antibiotics in pharmaceutical formulations and biological fluids via binary complex formation with eosin and spectrophotometry. J AOAC Int.2007;90:1579–1587.
11.Al-Rimawi F, Kharoaf M. Analysis of azithromycin and its related compounds by RP-HPLC with UV detection. J Chromatogr Sci.2010;48:86–90.
12.Beckett AH, Stenlake JB. Ultraviolet-visible absorption spectrophotometry. Practical pharmaceutical chemistry, 4th Ed, Part II. New Delhi, CBS Publishers and distributors,2005:275–337.
13.El-Gazayerly ON. Characterization and evaluation of tenoxicam coprecipitates. Drug Dev Ind Pharm. 2000;26:925–930.
14.Margarit MV, Rodríguez IC, Cerezo A. Physical characteristics and dissolution kinetics of solid dispersions of ketoprofen and polyethylene glycol 6000. Int J Pharm. 1994;108:101–107.
15.Arora SC, Sharma PK, Irchhaiya R, Khatkar A, Singh N, Gagoria J. Development, characterization and solubility study of solid dispersions of azithromycin dihydrate by solvent evaporation method. J Advan Pharm Technol Res. 2010;1:221.
16.Rawat S, Jain SK. Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur J Pharm Biopharm.2004;57:263–267.
17.Martin AN, Swarbrick J, Commarata A. Physical Pharmacy, 3rd edition. Philadelphia: Lea and Febiger; 1983:423–425.
18.Sangram S, Surwase D, Kore KJ, Bagade MY, Shete RV. Dissolution enhancement of poorly soluble azithromycin using solid dispersion method. Euro J Pharm & Med Res.2015:2;314–323.
19.Arias MJ, Gines JM, Moyano JR, Perez-Martinez JI, Rabasco AM.Influence of the preparation method of solid dispersions on their dissolution rate: study of triamterene-D-mannitol system. Int J Pharm. 1995;123:25–31.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case report
R. Ajitha Nancy Rani*,V. Hemavathy
Sree Balaji College of Nursing, Chromepet,Chennai, Tamil Nadu, India 600044
Address reprint requests to:
*Dr. R. Ajitha nancy rani
Sree Balaji College of Nursing, Chromepet,Chennai, Tamil Nadu, India 600044
Article citation: Rani RAN, Hemavathy V.Post-traumatic stress disorder a case study.J Pharm Biomed Sci 2016;06(10):546–547.
ABSTRACT
Post traumatic stress disorder is a set of reaction to an extreme stressor such as intense fear, helplessness or horror that leads the individual to relieve the trauma. The disorder may occur at any age1. Symptoms may begin within the first 3 months after the trauma,or there may be delay of several months or even years.
Objective To define post traumatic stress disorder, incidence, aetiology, symptoms, diagnostic evaluation, treatment, medical management.
Method Describing the symptomatology, aetiology of post-traumatic stress disorder.
Result Fifty-year-old female, presented with the history of losing his only son after the flood in Chennai on December 2015. She detached herself from others, unresponsiveness to the surrounding and finally diagnosed as post traumatic stress disorder and was treated for it.
Conclusion It is a neurotic disorder, associated with events that would be distressing, include family members in providing an effective care to the patient and to develop support and explore the emotional experience of client.
KEYWORDS post-traumatic stress disorder, trauma, neurotic disorder, emotional experience
REFERENCES
1.American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA:American Psychiatric Publishing.
2.National Collaborating Centre for Mental Health (UK) (2005).“Post-Traumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care”.
3.Zolad Zoladz PR, Diamond DM. Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature. Neurosci Biobehav Rev 2013;37:860–895.
4.All in the Mind. Australian Broadcasting Commission. 9 October 2004.
5.van der Kolk, B (2014). The Body Keeps the Score: Brain, Mind,and Body in the Healing of Trauma. New York: Penguin.
6.Herman J (2015). Trauma and recovery: the aftermath of violence–from domestic abuse to political terror. 2nd ed.New York: Basic Books.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Anand Rajderkar1, Ranjeet Bapat2,Mitul Kumar Mishra3*,Priyanka Kadoo3
1 Department of Oral Pathology, SDKS DentalCollege and Hospital, Nagpur
2 International Medical University, Kuala Lumpur, Malaysia
3 Department of Periodontology, SDKS Dental College and Hospital, Nagpur
Address reprint requests to:
*Dr. Mitul Kumar Mishra,
Assistant Professor, Department of Periodontology,SDKS Dental College and Hospital,Nagpur, Maharashtra, India
Article citation: Rajderkar A, Bapat R,Mishra MK, Kadoo P. Pathogenesis of diabetes and periodontal health–a twoway connection. J Pharm Biomed Sci 2016;06(10):548–550.
Available at www.jpbms.info
ABSTRACT
Periodontitis has been traditionally regarded as a chronic inflammatory oral infection. However, recent studies indicate that this oral disease may have profound effects on systemic health. Periodontitis is an infection that is twice as prevalent in diabetic individuals compared to non-diabetics. Porphyromonas gingivalis, one of the microorganisms responsible for this infection, is able to invade endothelial cells and is a potent signal for monocyte and macrophage activation. Thus, once established in the diabetic host,this chronic infection complicates diabetes control and increases the occurrence and severity of microvascular and macrovascular complications. Persistent elevation of IL-1 beta, IL-6, and TNF-alpha in the diabetic state have an effect on the liver, stimulate the release of acute-phase proteins, produce the characteristic dysregulation of lipid metabolism associated with type 2 diabetes, and have effects on pancreatic beta cells as well. In addition, TNF-alpha, a potent inhibitor of the tyrosine kinase activity of the insulin receptor, has been implicated as an etiologic factor for insulin resistance. Collectively, the evidence supports a role for cytokine elevation in the pathophysiology and metabolic abnormalities associated with diabetes. It has been reported that for every person known to have diabetes, there are many individuals in whom the disease remains undiagnosed.
It means that dentists will regularly encounter diabetic patients in their clinic. This review emphasizes the possible role of diabetes on the periodontal health of the patient and the ways in which untreated periodontitis may influence the course of diabetes.
KEYWORDS periodontitis, diabetes mellitus, IDDM, NIDDM
REFERENCES
1. Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranza’s Clinical Periodontology, 12th Edition, California, Saunders 2014.
2. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1998;21(suppl 1):523.
3. Bartlett JG. Anaerobic infections of the lung. Chest. 1987:91:901–909.
4. Löe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care. 1993;16:329–34.
5. Rees TD. Periodontal management of the patient with diabetes mellitus. Periodontol. 2000;23:63–72.
6. Mariotti A. Dental plaque-induced gingival disease. Ann Periodontol.1999;4:7–19.
7. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE,et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol. 1994;65:260–7.
8. Bridges RB, Anderson JW, Saxe SR, Gregory K, Bridges SR.Periodontal status of diabetic and non-diabetic men: effects of smoking, glycemic control, and socioeconomic factors. J Periodontol.1996;67:1185–92.
9. Tervonen T, Karjalainen K. Periodontal disease related to diabetic status. A pilot study of the response to periodontal therapy in type 1 diabetes. J Clin Periodontol. 1997;24:505–10.
10. Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. A proposed model linking inflammation to obesity, diabetes and periodontal infections. J Periodontol. 2005;76:2075–84.
11. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus:A two-way relationship. Ann Periodontol. 1998;3:51–61.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial
support, publication of this research, patents,and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.